A Pivotal Phase 3 Study of APC-1000 (Beclomethasone HFA) in Asthmatics

Trial Profile

A Pivotal Phase 3 Study of APC-1000 (Beclomethasone HFA) in Asthmatics

Phase of Trial: Phase III

Latest Information Update: 10 May 2018

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Adamis Pharmaceuticals Corporation
  • Most Recent Events

    • 10 May 2018 According to Adamis Pharmaceuticals Corporation media release, the company received approval for APC-1000 from the FDA to proceed with phase 3 clinical studies.The company expects to initiate this trial in 2018.
    • 22 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top